At the event company management and infectious disease key opinion leaders discussed scientific, regulatory, and commercial considerations with respect to Moderna’s vaccine programs and the vaccine space more broadly.
“Not surprisingly, SARS-CoV-2, the virus behind the Covid-19 outbreak featured prominently, with discussions of the virus itself, Moderna’s clinical plan (now enrolling the highest [250 µg] dose cohort in the phase I trial, and an amendment to add elderly participants), and manufacturing scale-up” wrote Chardan analyst Geula Livshits following the event.
Livshits, who has a buy rating and $40 price target on MRNA, anticipates initial phase I immunogenicity data in the summer, aiming for a rapid move into phase II, with phase IIb/III studies coming in the fall after a dose has been selected.
Moderna also announced interim data from the phase I trial of its 2nd generation Zika vaccine (mRNA-1893), demonstrating neutralizing antibody titers and efficient seroconversion with 10 and 30 µg doses.
Finally, presentations from multiple key opinion leaders highlighted both the unmet needs and the economic opportunity for vaccines that prevent respiratory infections as well as transmission of Zika and cytomegalovirus from the mother to the fetus.
So far year-to-date the stock has rallied by over 90%, and analysts continue to believe that MRNA makes a compelling investment. Indeed, TipRanks shows that the stock holds a Strong Buy analyst consensus with eight buy ratings in the last three months vs only one hold rating. (See Moderna’s stock analysis on TipRanks)
Arcus Surges 50% In After-Hours Trading On Rumored Gilead Stake
GILD: Second Covid-19 Study of Remdesivir in China Suspended
The Race Continues for a COVID-19 Vaccine; 3 Healthcare Stocks to Watch